Synthesis and pharmacological evaluation of dual acting ligands targeting the adenosine A2A and dopamine D2 receptors for the potential treatment of Parkinson's disease.

A relatively new strategy in drug discovery is the development of dual acting ligands. These molecules are potentially able to interact at two orthosteric binding sites of a heterodimer simultaneously, possibly resulting in enhanced subtype selectivity, higher affinity, enhanced or modified physiological response, and reduced reliance on multiple drug administration regimens. In this study, we have successfully synthesized a series of classical heterobivalent ligands as well as a series of more integrated and drug-like dual acting molecules, incorporating ropinirole as a dopamine D-2 receptor agonist and ZM 241385 as an adenosine A(2)A receptor antagonist. The best compounds of our series maintained the potency of the original pharmacophores at both receptors (adenosine A(2)A and dopamine D-2). In addition, the integrated dual acting ligands also showed promising results in preliminary bloodbrain barrier permeability tests, whereas the classical heterobivalent ligands are potentially more suited as pharmacological tools.